Digoxin assays: Frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids

Clinical Chemistry

Volumn 48, Issue 3, 2002, Pages 507-516

  Steimer, Werner ^a   Müller, Christine ^a   Eber, Barbara ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 7 THIOMETHYLSPIRONOLACTONE; 7 THIOMETHYLSPIROLACTONE; 7 THIOSPIROLACTONE; CANRENOATE POTASSIUM; CANRENONE; DIGOXIN; DRUG METABOLITE; HYDROCORTISONE; PREDNISOLONE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL ERROR; ARTICLE; ASCITES; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG INTOXICATION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; PATIENT MONITORING; ULTRAFILTRATION;

EID: 0036180970     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.3.507     Document Type: Article

References (38)

1. Digoxin and its related endogenous factors
2. Intoxication due to negative canrenone interference in digoxin drug monitoring
3. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: Mutagenic metabolites unique to potassium canrenoate
4. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
5. The effect of spironolactone and canrenone on the digoxin RIA
6. The influence of intravenous canrenoate on the determination of digoxin in serum by radio- and enzyme-immunoassay
7. Spironolactone-associated digoxin RIA interference
8. Influence of spironolactone and its metabolite canrenone on serum digoxin assays
9. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays
10. Suppression of immunoassay results by cross-reactivity
11. Suppression of total digoxin concentrations by digoxin-like immunoreactive substances in the MEIA digoxin assay. Elimination of negative interference by monitoring free digoxin concentrations
12. Endogenous digoxin-like substance in liver failure
13. Multicenter study of Abbott AxSYM digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive factors
14. 125I-RIA at two Australian centers
15. Syva Emit 2000 and Roche "on line" subject to less interference by digoxin-like factors than Abbott TDx FPIA in newborns and pregnant women
16. Resolving discrepant digoxin results: A case study involving multiple interferences
17. Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind)
18. Monitoring of unbound digoxin in patients treated with anti-digoxin antigen-binding fragments: A model for the future?
19. Standards of laboratory practice: Cardiac drug monitoring
20. Unexpected suppression of total digoxin concentrations by cross-reactants in the microparticle enzyme immunoassay: Elimination of interference by monitoring free digoxin concentration
21. Spironolactone. I. Disposition and metabolism
22. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone
23. Digoxin-like immunoreactive substance: Monoclonal and polyclonal RIA and FPlA compared
24. The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays
25. The interference of spironolactone, canrenone and three metabolites in nine immunoassays for the analysis of digoxin
26. Analysis of metabolites - A new approach to bioequivalence studies of spironolactone formulations
27. Falsely increased digoxin concentrations in patients with liver disease
28. Digoxin-like immunoreactive substance (DLIS) in liver disease: Comparison of clinical and laboratory parameters in patients with and without DLIS
29. Spironolactone interference with digoxin RIA in cirrhotic patients
30. Correlation between serum albumin and digoxin-like immunoreactive substance in liver disease
31. Digoxin-like immunoreactive substances in chronic liver disease
32. Comparability of a new turbidimetric digoxin test with other immunochemical tests and with HPLC - A multicenter evaluation
33. Drug interferences with plasma assays in therapeutic drug monitoring
34. Bidirectional (positive/negative) interference in a digoxin immunoassay: Importance of antibody specificity
35. Positive and negative interference of the Chinese medicine Chan Su in serum digoxin measurement. Elimination of interference by using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin concentration
36. False low digoxin readings in every 40th patient! Canrenone and spironolactone interference in the Abbott AxSYM MEIA II assay
37. Assessment of aldosterone inhibitors on digoxin immunoassay performance